Answers are grounded in this paper and cite their sources.
Purpose To review the efficacy, safety, and durability of teprotumumab (TEP) in the treatment of dysthyroid optic neuropathy (DON).Methods A PROSPERO-registered systematic review (CRD420261442289) was conducted in accordance with PRISMA 2020 guidelines. Five databases were searched through July 2026. Studies reporting 1 or more patients with DON managed with TEP were included.Results Fourteen studies comprising 52 patients (81 eyes) were included. The sample-weighted mean age was 66.5 years and 29 of 46 patients with documented sex (63.0%) were female. Prior corticosteroids had been administered in 50 patients (96.2%) and orbital decompression in 20 patients (38.5%), while only 2 patients (3.8%) were treatment-naïve. Visual acuity improved in 39 of 44 eyes (88.6%) with individual paired data. Colour vision improved in all 39 assessable eyes (100%). The weighted mean proptosis reduction was 4.2 mm across 77 eyes (range, 1–10 mm) and mean clinical activity score improvement was 4.98 points (23 patients). Rapid optic nerve response within two infusions occurred in 32 of 49 assessable patients (65.3%). Diplopia resolved in only 4 of 11 evaluable patients (36.4%). Across 42 evaluable patients, 3 experienced TED relapse and 3 patients developed DON recurrence. Adverse events included hearing loss, tinnitus or dysacusis (n = 6), hyperglycaemia (n = 4), muscle spasms and gastrointestinal distress (n = 4).Conclusion Teprotumumab produces rapid recovery of optic nerve function, clinical activity, and proptosis as salvage therapy for DON. Recurrent DON and TED reactivation are, however, not uncommon with uncertain durability of response.
No takes yet. Share an insight, caveat, or question.
Agarwal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: